Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that a Phase 3 clinical trial, ODYSSEY ESCAPE evaluating their PCSK9 inhibitor Praluent (alirocumab) in patients with heterozygous familial hypercholesterolemia (HeFH) who require weekly/bi-weekly apheresis treatment, showed adding Praluent to existing therapy lowered LDL cholesterol (LDL-C) by ~50% from baseline versus a 2% increase for placebo. In addition, treatment with Praluent reduced the need for apheresis treatment by 75% compared to placebo (p<0.0001), the primary endpoint.